---
pmid: '23623661'
title: Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin
  B1/CDK1-phosphorylated nuclear iASPP.
authors:
- Lu M
- Breyssens H
- Salter V
- Zhong S
- Hu Y
- Baer C
- Ratnayaka I
- Sullivan A
- Brown NR
- Endicott J
- Knapp S
- Kessler BM
- Middleton MR
- Siebold C
- Jones EY
- Sviderskaya EV
- Cebon J
- John T
- Caballero OL
- Goding CR
- Lu X
journal: Cancer Cell
year: '2013'
full_text_available: false
doi: 10.1016/j.ccr.2013.03.013
---

# Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP.
**Authors:** Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X
**Journal:** Cancer Cell (2013)
**DOI:** [10.1016/j.ccr.2013.03.013](https://doi.org/10.1016/j.ccr.2013.03.013)

## Abstract

1. Cancer Cell. 2013 May 13;23(5):618-33. doi: 10.1016/j.ccr.2013.03.013. Epub
2013  Apr 25.

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin 
B1/CDK1-phosphorylated nuclear iASPP.

Lu M(1), Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, 
Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, 
Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X.

Author information:
(1)Ludwig Institute for Cancer Research, University of Oxford, Oxford OX3 7DQ, 
UK.

Erratum in
    Cancer Cell. 2016 Nov 14;30(5):822-823. doi: 10.1016/j.ccell.2016.09.019.

Comment in
    Pigment Cell Melanoma Res. 2014 Jan;27(1):8-10. doi: 10.1111/pcmr.12180.

Nearly 90% of human melanomas contain inactivated wild-type p53, the underlying 
mechanisms for which are not fully understood. Here, we identify that cyclin 
B1/CDK1-phosphorylates iASPP, which leads to the inhibition of iASPP 
dimerization, promotion of iASPP monomer nuclear entry, and exposure of its p53 
binding sites, leading to increased p53 inhibition. Nuclear iASPP is enriched in 
melanoma metastasis and associates with poor patient survival. Most wild-type 
p53-expressing melanoma cell lines coexpress high levels of phosphorylated 
nuclear iASPP, MDM2, and cyclin B1. Inhibition of MDM2 and iASPP phosphorylation 
with small molecules induced p53-dependent apoptosis and growth suppression. 
Concurrent p53 reactivation and BRAFV600E inhibition achieved additive 
suppression in vivo, presenting an alternative for melanoma therapy.

Copyright Â© 2013 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccr.2013.03.013
PMID: 23623661 [Indexed for MEDLINE]
